Anti-Obesity Drugs

Anti-Obesity Drugs

Global Anti-Obesity Drugs Market to Reach US$5.4 Billion by 2030

The global market for Anti-Obesity Drugs estimated at US$3.0 Billion in the year 2023, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.7% over the analysis period 2023-2030. Prescription Drugs, one of the segments analyzed in the report, is expected to record a 8.5% CAGR and reach US$4.9 Billion by the end of the analysis period. Growth in the OTC Drugs segment is estimated at 10.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$827.9 Million While China is Forecast to Grow at 7.9% CAGR

The Anti-Obesity Drugs market in the U.S. is estimated at US$827.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$812.2 Million by the year 2030 trailing a CAGR of 7.9% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.9% and 7.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 7.0% CAGR.

Global Anti-Obesity Drugs Market - Key Trends and Drivers Summarized

What Are Anti-Obesity Drugs and How Do They Work?

Anti-obesity drugs are medications designed to help individuals lose weight and maintain weight loss by targeting various physiological pathways involved in hunger, satiety, and fat absorption. These drugs function through different mechanisms such as appetite suppression, increasing feelings of fullness, reducing fat absorption from the diet, and enhancing energy expenditure. Commonly prescribed anti-obesity drugs include orlistat, which inhibits fat absorption in the intestines, and medications like liraglutide and phentermine-topiramate, which act on the central nervous system to reduce appetite. These drugs are typically prescribed for individuals with a Body Mass Index (BMI) of 30 or higher, or for those with a BMI of 27 or higher who have weight-related health conditions such as hypertension, type 2 diabetes, or dyslipidemia. The goal of these medications is to assist patients in achieving a sustainable weight loss that contributes to overall health improvement.

How Are Anti-Obesity Drugs Utilized in Clinical Practice?

In clinical practice, anti-obesity drugs are part of a comprehensive weight management plan that includes lifestyle modifications such as diet, exercise, and behavioral therapy. Physicians typically evaluate a patient`s health status, weight history, and weight-loss goals before prescribing these medications. The effectiveness and safety of anti-obesity drugs are closely monitored through regular follow-up appointments. Patients are often advised to adhere to a reduced-calorie diet and increase physical activity to maximize the benefits of the medication. In some cases, anti-obesity drugs are used as an adjunct to bariatric surgery, either preoperatively to reduce surgical risks or postoperatively to maintain weight loss. The integration of pharmacotherapy with lifestyle interventions aims to achieve long-term weight management and mitigate the health risks associated with obesity, such as cardiovascular disease, type 2 diabetes, and certain cancers.

What Are the Recent Innovations in Anti-Obesity Drug Development?

The field of anti-obesity drug development has seen significant advancements driven by a deeper understanding of the biological mechanisms underlying obesity. Recent innovations include the development of GLP-1 receptor agonists like semaglutide, which mimic the effects of the gut hormone GLP-1 to enhance satiety and reduce appetite. Semaglutide has shown promising results in clinical trials, with significant weight loss outcomes compared to existing therapies. Another exciting area of research is the development of dual agonists that target multiple metabolic pathways simultaneously, such as tirzepatide, which acts on both GLP-1 and GIP receptors to regulate glucose and energy balance. Additionally, novel drug delivery systems, including long-acting injectables and oral formulations, are being explored to improve patient adherence and convenience. Advances in genomics and personalized medicine are also paving the way for more tailored obesity treatments, allowing for more precise targeting of specific patient populations based on genetic and metabolic profiles.

What Factors Are Driving the Growth in the Anti-Obesity Drugs Market?

The growth in the anti-obesity drugs market is driven by several factors. The rising prevalence of obesity worldwide, exacerbated by sedentary lifestyles and unhealthy dietary habits, is a primary driver, creating a substantial demand for effective weight management solutions. Technological advancements in drug development, including novel mechanisms of action and innovative delivery methods, are enhancing the efficacy and safety profiles of anti-obesity medications, attracting more healthcare providers and patients. Increased awareness of the health risks associated with obesity, coupled with growing acceptance of pharmacotherapy as a viable weight management option, is also contributing to market growth. Regulatory approvals and favorable reimbursement policies in several regions are facilitating the accessibility and affordability of these drugs. Furthermore, the expanding research on the metabolic and genetic factors influencing obesity is leading to the development of more targeted and personalized treatments, further boosting the market. Collectively, these factors underscore the dynamic expansion of the anti-obesity drugs market, reflecting its critical role in addressing the global obesity epidemic.

Select Competitors (Total 23 Featured) -

• Eisai Co. Ltd. (Japan)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• GlaxoSmithKline Plc
• Novo Nordisk A/S (Denmark)
• Rhythm Pharmaceuticals (US)
• VIVUS Inc. (US)

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.